DAEJEON, South Korea, September 1, 2020
/PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage
biotechnology company in South Korea, announced today that on September 4th,
the company will present the interim data of its ongoing olinivacimab plus pembrolizuamb
combination trials at KSMO 2020.
KSMO 2020 is the 13th annual conference hosted
by Korean Society of Medical Oncology (KSMO), the largest cancer organization
in South Korea. Through this event, the organization will facilitate meetings among
members, promote research in clinical oncology, and cultivate cooperation with clinical
oncologists around the world.
Dr. Jin-San Yoo, CEO of PharmAbcine,
will present the interim data as of two combination trials (Phase 1b), one for
mTNBC (metastatic Triple-Negative Breast Cancer) patients and the other for
rGBM (recurrent Glioblastoma Multiforme) patients. The first mTNBC patient came
in on October 2018 whereas the first rGBM patient came in on January 2019. will
end within this year.
“We are honored to be invited and excited to
share and discuss interim clinical data with global leading medical oncologists,”
said Dr. Yoo. “We particularly find the mTNBC data quite encouraging.”
Because of the COVID-19 pandemic, the
organizing committee will hold the conference digitally to ensure the safety of
1428 participants. The event will be broadcasted online for two days of
September 3rd and 4th, 2020.
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotech company focusing on the
development of fully human antibody therapeutics to treat neovascular
disorders, tumors, and other medically unmet diseases. It provides therapeutic
antibodies for a wide spectrum of indications from oncology, immuno-oncology,
ophthalmology, respiratory, to renal pathology.
PharmAbcine has its own HuPhage library and innovative selection
system. PharmAbcine's advanced 3G expression system accommodates high levels of
antibody production with high reproducibility. With its highly advanced
technology platforms, it provides high-quality antibody generation services.
The high standards have allowed PharmAbcine to expand co-development opportunities
with not only existing but also potential partners.
Additional information about PharmAbcine can be found on our
website at http://www.pharmabcine.com.